ClinicalTrials.gg
Active, not recruitingNCT06440967Updated Oct 27, 2026

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

A Phase 3 interventional study of Fezolinetant and Placebo in Hot Flashes, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 110 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
982
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
2nd of 16
982 · median 249
Started
2024
with 2 others
Phase 3
10 of 16
2 open now
Registered
11th of 16
by date
Lead sponsor
6 of 16
Astellas Pharma Global Development, Inc.

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 2nd largest by enrollment, is one of 3 that started in 2024, is one of 10 in phase 3, and was the 11th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but cannot be given to women on hormone therapy for breast cancer. Fezolinetant, an alternative to HRT, treats hot flashes for women in menopause. As hot flashes happen in the same way for women on hormone therapy for breast cancer, fezolinetant could help these women. In this study, women on hormone therapy for breast cancer who have moderate to severe hot flashes will take part. They will either take fezolinetant or a placebo to treat their hot flashes. The placebo looks like fezolinetant but doesn't have any medicine in it.

The main aim of this study is to confirm if women who take fezolinetant have fewer hot flashes that are less severe compared to women who take the placebo.

Women 18 years or older seeking treatment for hot flashes. They can take part in the study if they have an average of 7 or more moderate to severe hot flashes each day. They are having hormone therapy for breast cancer from stage 0 (cancer cells that have not spread to nearby tissue) up to stage 3+ (the cancer has spread from the breast to the lymph nodes near the breast or the chest wall).

The women will be assigned 1 of 2 study treatments (fezolinetant or placebo) by chance alone. Treatment will be double-blinded. That means that the women in the study and the study doctors will not know who takes which of the study treatments (fezolinetant or placebo). Women who take part in the study will take 1 tablet every day for 52 weeks (1 year). Each woman will be given an electronic handheld device with an app to track their hot flashes on a daily basis. Some women may be able to use the app on their own smartphone. They will also use another device to answer questions about how hot flashes affect their daily life. During the study, the women will visit their study clinic about every 4 weeks for a health check. The last clinic visit will be 3 weeks after the women take their last tablet of study treatment (fezolinetant or placebo). After this visit the women will be called twice to check their health. The women will be in the study for about 2 years.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • ESN364;
  • vasomotor symptoms;
  • fezolinetant;
  • VEOZAH™
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a personal history of stage 0-3 hormone receptor positive (HR+), either human epidermal growth factor receptor (HER)-2+ or - breast cancer; appropriate documentation includes a written or electronic report.
  • Participant must be receiving stable maintenance endocrine therapy (e.g., tamoxifen or aromatase inhibitors, such as anastrozole, letrozole and exemestane) with or without gonadotropin-releasing hormone (GnRH) agonists/antagonists for a minimum of 4 months prior to randomization and be planning to continue on adjuvant endocrine therapy for the duration of the trial without change to therapy, brand or dose. If the participant is taking GnRH agonists/antagonists, therapy must also be stable for a minimum of 4 months prior to randomization. Add-on therapies for breast cancer adjuvant treatment (e.g., cyclin dependent kinase-4 (CDK4) inhibitors) are allowed.
  • Participant has a minimum average of 7 moderate to severe hot flashes (HFs) (vasomotor symptoms (VMS)) per day as recorded in the electronic daily diary (data must be available for at least 7 of the last 10 days prior to randomization).
  • Has an European Cooperative Oncology Group () score 0 or 1.
  • Has at least 12-month life expectation.
  • Participant is born female.
  • Female participant: Is not pregnant and at least 1 of the following conditions apply:

    • Not a woman of (WOCBP)
    • WOCBP who has a negative urine or serum pregnancy test at screening and day 1 and agrees to follow the guidance from the time of through at least 30 days after final study intervention administration.
  • Female participant: Must not be breastfeeding or lactating starting at screening and while the participant is taking investigational study intervention and for 30 days after final investigational study intervention administration.
  • Female participant: Must not donate ova starting at first administration of study intervention and while the participant is taking investigational study intervention and for 30 days after final investigational study intervention administration.
  • Participant agrees not to participate in another interventional study while participating in the present study until the end of the 1-year extension follow-up period.
  • Participant's condition is stable as determined on the basis of medical history and general physical examination, hematology and biochemistry parameters, pulse rate and/or blood pressure and (ECG) (or showing no deviations obtained within the last 3 months or at screening).
  • Participant has no new clinically significant findings on breast examination or from imaging (mammogram, breast ultrasound or equivalent). Results indicate that the participant is a good candidate for the study. Appropriate documentation includes a written or electronic report. In case of double mastectomy, imaging is not needed.
  • Participant has a negative serology panel (including surface antigen (HBsAg), virus (HCV) antibody and (HIV) antibody screens).

Exclusion criteria

Exclusion Criteria:

  • Participant has diagnosis of breast cancer (stage 4).
  • Participant has current or history (except complete remission for 5 years or more prior to signing ) of any except for HR+ breast cancer (stage 0 to 3) or basal cell carcinoma.
  • Participant has had surgery or non-surgical (chemotherapy or radiotherapy) treatment for breast cancer within the last 3 months prior to signing informed consent.
  • Participant has active liver disease, jaundice, or elevated liver aminotransferases ( (ALT) or aspartate aminotransferase (AST)), elevated total (TBL) or direct bilirubin (DBL), or elevated alkaline phosphatase (ALP) at screening. A participant with mildly elevated ALT or AST up to \< 2 × (ULN) can be enrolled if TBL and DBL are normal. Participant with mildly elevated ALP (up to \< 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Participant with Gilbert's syndrome with elevated TBL may be enrolled as long as DBL, and reticulocytes are normal.
  • Participant has creatinine > 1.5 x ULN; or estimated (eGFR) using the Modification of Diet in Renal Disease formula \< 30 mL/min/1.73 m2 at the screening visit.
  • Participant has a history of endometrial hyperplasia (participant can be enrolled if she has undergone a hysterectomy) or uterine/endometrial cancer.
  • Participant has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) or malignancy that could confound interpretation of the study outcome.
  • Participant uses a prohibited therapy (menopause hormone therapy (MHT), estradiol-containing hormonal progestin and progesterone-only medicines, any treatment for VMS [prescription medications, over-the-counter, or herbal] or CYP1A2 (cytochrome P450) inhibitors) or is not willing to wash out such drugs; in addition, medications that are due to underlying breast cancer diagnosis and the endocrine therapy.
  • Participant has a known substance abuse or alcohol addiction within 6 months of screening.
  • Participant has received any therapy within 90 days or 5 half-lives, whichever is longer, prior to screening.
  • Participant has any condition, which makes the participant unsuitable for study participation.
  • Participant has a known or suspected to fezolinetant, the adjuvant endocrine therapy being used, or any components of the formulations used.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
982 participants (actual)

Study arms

  • Experimental
    Fezolinetant

    Participants taking tamoxifen or an aromatase inhibitor will receive fezolinetant once daily for 52 weeks. After the end of the 52 week treatment period, participants will continue to participate in the extension follow up until week 104. They will continue to receive the adjuvant endocrine therapy as needed.

    Drug: Fezolinetant · Drug: Tamoxifen · Drug: Aromatase inhibitor

  • Placebo comparator
    Placebo

    Participants taking tamoxifen or an aromatase inhibitor will receive matching placebo once daily for 52 weeks. After the end of the 52 week treatment period, participants will continue to participate in the extension follow up until week 104. They will continue to receive the adjuvant endocrine therapy as needed.

    Drug: Placebo · Drug: Tamoxifen · Drug: Aromatase inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from Baseline to Week 4 in the frequency of moderate to severe VMS

    Frequency of moderate and severe vasomotor symptoms (VMS) events will be calculated as the sum of moderate and severe VMS events per day.

    Time frame: Baseline to Week 4

  2. Mean change from Baseline to Week 12 in the frequency of moderate to severe VMS

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day.

    Time frame: Baseline to Week 12

  3. Mean change from Baseline to Week 4 in the severity of moderate to severe VMS

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline to Week 4

  4. Mean change from Baseline to Week 12 in the severity of moderate to severe VMS

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Mean change from Baseline to Week 12 in the MENQOL VMS 1 week recall domain score

    The Menopause-specific Quality of Life Questionnaire (MENQOL) is a 29-item patient-reported outcome (PRO) measure that assesses the impact of 4 domains of menopausal symptoms, as experienced over the last week: vasomotor, psychosocial, physical and sexual. Each item score ranges from 1 to 8, and each domain is scored separately; each domain mean ranges from 1 to 8. The overall questionnaire score is the mean of the domain means. Higher scores represent more bothersome menopausal symptoms. A reduction (improvement) of 1 is the minimum clinically important difference in MENQoL.

    Time frame: Baseline to Week 12

  2. Mean Change from Baseline to Week 12 in the PROMIS SD SF 8b Total (raw) Score

    The Patient-reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b) assesses self-reported sleep disturbance over the past 7 days and includes perceptions of: restless sleep; satisfaction with sleep; refreshing sleep; difficulties sleeping, getting to sleep or staying asleep; amount of sleep; and sleep quality. Responses to each of the 8 items range from 1 to 5 and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS SD SF 8b indicate more of the concept measured (disturbed sleep).

    Time frame: Baseline to Week 12

  3. Mean change from Baseline to Week 24 in the frequency of moderate to severe VMS

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day.

    Time frame: Baseline to Week 24

  4. Mean Change from Baseline to Week 24 in the severity of moderate to severe VMS

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline to Week 24

  5. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    A TEAE is defined as Adverse Event (AE) observed after starting administration of the investigational study intervention and up to 21 days after the last dose of investigational study intervention.

    Time frame: Up to Week 55

  6. Number of participants with Adverse Events of Special Interest (AESIs)

    AEs of special interest in this study will include: Progression of breast cancer including metastasis; Adverse events of uterine bleeding; Adverse events of liver test elevations; Any liver AE leading to discontinuation.

    Time frame: Up to Week 55

  7. Number of participants with laboratory value abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to Week 55

  8. Number of participants with vital sign abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to Week 55

  9. Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to Week 52

  10. Mean change from Baseline in the frequency of moderate to severe VMS to the average frequency of moderate to severe VMS over Weeks 1 to 3

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day.

    Time frame: Baseline and Weeks 1 to 3

  11. Mean Change from Baseline in the frequency of moderate to severe VMS to the average frequency of moderate to severe VMS over Weeks 5 to 11

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day.

    Time frame: Baseline and Weeks 5 to 11

  12. Mean change from Baseline in the severity of moderate to severe VMS to the average severity of moderate to severe VMS over weeks 1 to 3

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline and Weeks 1 to 3

  13. Mean Change from Baseline in the severity of moderate to severe VMS to the average severity of moderate to severe VMS over weeks 5 to 11

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline and Weeks 5 to 11

  14. Percent reduction >/= 50% in the frequency of moderate and severe VMS from baseline

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day. Percent reduction of \>/= 50% will be reported.

    Time frame: Baseline to Weeks 1, 4, 8 and 12

  15. Percent reduction >/= 75% in the frequency of moderate and severe VMS from baseline

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day. Percent reduction of \>/= 75% will be reported.

    Time frame: Baseline to Weeks 1, 4, 8 and 12

  16. Percent reduction at 100% in the frequency of moderate and severe VMS from baseline

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day. Percent reduction of 100% will be reported.

    Time frame: Baseline to Weeks 1, 4, 8 and 12

  17. Pharmacokinetics (PK) of Fezolinetant in Plasma: Apparent Clearance (CL/F) for participants taking tamoxifen

    CL/F will be derived using a population PK model.

    Time frame: Up to Week 24

  18. Pharmacokinetics (PK) of Fezolinetant in Plasma: Apparent Clearance (CL/F) for participants taking aromatase inhibitors

    CL/F will be derived using a population PK model.

    Time frame: Up to Week 24

  19. PK of Fezolinetant in Plasma: apparent volume of distribution (Vc/F) for participants taking tamoxifen

    Vc/F will be derived using a population PK model.

    Time frame: Up to Week 24

  20. PK of Fezolinetant in Plasma: apparent volume of distribution (Vc/F) for participants taking aromatase inhibitors

    Vc/F will be derived using a population PK model.

    Time frame: Up to Week 24

  21. PK of Fezolinetant in Plasma: average concentration (Cavg) for participants taking tamoxifen

    Cavg will be derived using a population PK model.

    Time frame: Up to Week 24

  22. PK of Fezolinetant in Plasma: Cavg for participants taking aromatase inhibitors

    Cavg will be derived using a population PK model.

    Time frame: Up to Week 24

  23. PK of Fezolinetant in Plasma: trough concentration (Ctrough) for participants taking tamoxifen

    Ctrough will be derived using a population PK model.

    Time frame: Up to Week 24

  24. PK of Fezolinetant in Plasma: Ctrough for participants taking aromatase inhibitors

    Ctrough will be derived using a population PK model.

    Time frame: Up to Week 24

  25. PK of tamoxifen in Plasma: CL/F

    CL/F will be derived using a population PK model.

    Time frame: Up to Week 24

  26. PK of tamoxifen in Plasma: Vc/F

    Vc/F will be derived using a population PK model.

    Time frame: Up to Week 24

  27. PK of tamoxifen in Plasma: Cavg

    Cavg will be derived using a population PK model.

    Time frame: Up to Week 24

  28. PK of tamoxifen in Plasma: Ctrough

    Ctrough will be derived using a population PK model.

    Time frame: Up to Week 24

  29. PK of tamoxifen Metabolite 4-OH tamoxifen in Plasma: CL/F

    CL/F will be derived using a population PK model.

    Time frame: Up to Week 24

  30. PK of tamoxifen Metabolite 4-OH tamoxifen in Plasma: Vc/F

    Vc/F will be derived using a population PK model.

    Time frame: Up to Week 24

  31. PK of tamoxifen Metabolite 4-OH tamoxifen in Plasma: Cavg

    Cavg will be derived using a population PK model.

    Time frame: Up to Week 24

  32. PK of tamoxifen Metabolite 4-OH tamoxifen in Plasma: Ctrough

    Ctrough will be derived using a population PK model.

    Time frame: Up to Week 24

  33. PK of tamoxifen Metabolite N-desmethyltamoxifen in Plasma: CL/F

    CL/F will be derived using a population PK model.

    Time frame: Up to Week 24

  34. PK of tamoxifen Metabolite N-desmethyltamoxifen in Plasma: Vc/F

    Vc/F will be derived using a population PK model.

    Time frame: Up to Week 24

  35. PK of tamoxifen Metabolite N-desmethyltamoxifen in Plasma: Cavg

    Cavg will be derived using a population PK model.

    Time frame: Up to Week 24

  36. PK of tamoxifen Metabolite N-desmethyltamoxifen in Plasma: Ctrough

    Ctrough will be derived using a population PK model.

    Time frame: Up to Week 24

  37. PK of tamoxifen Metabolite endoxifen in Plasma: CL/F

    CL/F will be derived using a population PK model.

    Time frame: Up to Week 24

  38. PK of tamoxifen Metabolite endoxifen in Plasma: Vc/F

    Vc/F will be derived using a population PK model.

    Time frame: Up to Week 24

  39. PK of tamoxifen Metabolite endoxifen in Plasma: Cavg

    Cavg will be derived using a population PK model.

    Time frame: Up to Week 24

  40. PK of tamoxifen Metabolite endoxifen in Plasma: Ctrough

    Ctrough will be derived using a population PK model.

    Time frame: Up to Week 24

  41. PK of aromatase inhibitors in Plasma: CL/F

    CL/F will be derived using a population PK model.

    Time frame: Up to Week 24

  42. PK of aromatase inhibitors in Plasma: Vc/F

    Vc/F will be derived using a population PK model.

    Time frame: Up to Week 24

  43. PK of aromatase inhibitors in Plasma: Cavg

    Cavg will be derived using a population PK model.

    Time frame: Up to Week 24

  44. PK of aromatase inhibitors in Plasma: Ctrough

    Ctrough will be derived using a population PK model.

    Time frame: Up to Week 24

  45. Mean change from Baseline in the MENQOL Total Score

    The MENQOL is a 29-item PRO measure that assesses the impact of 4 domains of menopausal symptoms, as experienced over the last week: vasomotor, psychosocial, physical and sexual. The total score is the mean of the domain means. Higher scores represent more bothersome menopausal symptoms. A reduction (improvement) of 1 is the minimum clinically important difference for the MENQoL.

    Time frame: Baseline to Weeks 4, 8, 12 and 24

  46. Mean change from Baseline in the MENQOL VMS 1-week recall domain score

    The MENQOL is a 29-item PRO measure that assesses the impact of 4 domains of menopausal symptoms, as experienced over the last week: vasomotor, psychosocial, physical and sexual. Each item score ranges from 1 to 8, and each domain is scored separately; each domain mean ranges from 1 to 8. Higher scores represent more bothersome menopausal symptoms.

    Time frame: Baseline to Weeks 4, 8 and 24

  47. Mean change from Baseline in the MENQOL psychosocial 1-week recall domain score

    The MENQOL is a 29-item PRO measure that assesses the impact of 4 domains of menopausal symptoms, as experienced over the last week: vasomotor, psychosocial, physical and sexual. Each item score ranges from 1 to 8, and each domain is scored separately; each domain mean ranges from 1 to 8. Higher scores represent more bothersome menopausal symptoms.

    Time frame: Baseline to Weeks 4, 8, 12 and 24

  48. Mean change from Baseline in the MENQOL physical 1-week recall domain score

    The MENQOL is a 29-item PRO measure that assesses the impact of 4 domains of menopausal symptoms, as experienced over the last week: vasomotor, psychosocial, physical and sexual. Each item score ranges from 1 to 8, and each domain is scored separately; each domain mean ranges from 1 to 8. Higher scores represent more bothersome menopausal symptoms.

    Time frame: Baseline to Weeks 4, 8, 12 and 24

  49. Mean change from Baseline in the MENQOL sexual 1-week recall domain score

    The MENQOL is a 29-item PRO measure that assesses the impact of 4 domains of menopausal symptoms, as experienced over the last week: vasomotor, psychosocial, physical and sexual. Each item score ranges from 1 to 8, and each domain is scored separately; each domain mean ranges from 1 to 8. Higher scores represent more bothersome menopausal symptoms.

    Time frame: Baseline to Weeks 4, 8, 12 and 24

  50. Mean change from Baseline in the PROMIS SD SF 8b Total (raw) Score

    The PROMIS SD SF 8b assesses self reported sleep disturbance over the past 7 days and includes perceptions of: restless sleep; satisfaction with sleep; refreshing sleep; difficulties sleeping, getting to sleep or staying asleep; amount of sleep; and sleep quality. Responses to each of the 8 items range from 1 to 5 and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS SD SF 8b indicate more of the concept measured (disturbed sleep).

    Time frame: Baseline to Weeks 4, 8 and 24

  51. Scores on the Patient Global Impression of Change (PGI-C) VMS

    The PGI-C VMS evaluates patient perceived change in hot flashes/night sweats from the initiation of treatment. Ratings range from (1) much better to (7) much worse.

    Time frame: Up to Week 24

  52. Change from Baseline in the Patient Global Impression of Severity (PGI-S) VMS Score

    The PGI-S VMS evaluates patient perceived severity of hot flashes/night sweats. Ratings range from (1) no problems to (4) severe problems.

    Time frame: Baseline to Weeks 4, 8, 12 and 24

  53. Scores on the PGI-C sleep disturbance (SD)

    PGI-C SD evaluates patient perceived change in sleep disturbance from the initiation of treatment. Ratings range from (1) much better to (7) much worse.

    Time frame: Up to Week 24

  54. Change from Baseline in the PGI-S SD Score

    The PGI-S SD evaluates patient perceived severity of sleep disturbance. Ratings range from (1) no problems to (4) severe problems.

    Time frame: Baseline to Weeks 4, 8, 12 and 24

  55. PGI-S SD response

    Proportion of patients achieving a response in PGI-S SD. The PGI-S SD evaluates patient perceived severity of sleep disturbance. Ratings range from (1) no problems to (4) severe problems. PGI-S SD response is defined as at least 2 levels of improvement on PGI-S SD from baseline. Non-response is defined as not achieving a response.

    Time frame: Up to Week 24

07

Study locations

110 sites
  • Site CA15019
    Sarnia, Ontario, Canada
  • Site CA15016
    Sault Ste. Marie, Ontario, Canada
  • Site CA15002
    Montreal, Quebec, Canada
  • Site CA15001
    Québec, Quebec, Canada
  • Site CA15004
    Québec, Quebec, Canada
  • Site CA15003
    Sherbrooke, Quebec, Canada
  • Site CA15020
    Victoriaville, Quebec, Canada
  • Site CA15007
    Trois-Rivières, Canada
  • Site CZ42006
    České Budějovice, Czechia
  • Site CZ42003
    Hořovice, Czechia
  • Site CZ42002
    Hradec Králové, Czechia
  • Site CZ42011
    Nový Jičín, Czechia
  • Site CZ42001
    Olomouc, Czechia
  • Site CZ42005
    Prague, Czechia
  • Site CZ42008
    Prague, Czechia
  • Site CZ42013
    Prague, Czechia
  • Site CZ42004
    Tábor, Czechia
  • Site CZ42007
    Vodňany, Czechia
  • Site CZ42009
    Vsetín, Czechia
  • Site DK45007
    Aalborg, Denmark
  • Site DE45003
    Esbjerg, Denmark
  • Site DK45009
    Hillerød, Denmark
  • Site DK45002
    Næstved, Denmark
  • Site DE45008
    Sønderborg, Denmark
  • Site FR33003
    Angers, France
  • Site FR33001
    Bayonne, France
  • Site FR33005
    Bordeaux, France
  • Site FR33018
    Bordeaux, France
  • Site FR33017
    Caen, France
  • Site FR33016
    Dijon, France
  • Site FR33013
    Le Mans, France
  • Site FR33007
    Lille, France
  • Site FR33012
    Lyon, France
  • Site FR33008
    Montpellier, France
  • Site FR33002
    Saint-Herblain, France
  • Site GR49005
    Essen, North Rhine-Westphalia, Germany
  • Site DE49001
    Bottrop, Germany
  • Site GR49013
    Dresden, Germany
  • Site DE49009
    Leipzig, Germany
  • Site DE49007
    Mönchengladbach, Germany
  • Site DE49010
    München, Germany
  • Site GR49003
    Münster, Germany
  • Site GR49014
    Wolfsburg, Germany
  • Site HU36008
    Budapest, Hungary
  • Site HU36006
    Debrecen, Hungary
  • Site HU36001
    Eger, Hungary
  • Site HU36002
    Kecskemét, Hungary
  • Site HU36010
    Salgótarján, Hungary
  • Site HU36003
    Székesfehérvár, Hungary
  • Site IT39011
    Bologna, Italy
  • Site IT39015
    Genova, Italy
  • Site IT39003
    Milan, Italy
  • Site IT39013
    Mirano, Italy
  • Site IT39017
    Pavia, Italy
  • Site IT39018
    Reggio Emilia, Italy
  • Site IT39012
    Terni, Italy
  • Site NL31010
    Breda, Netherlands
  • Site NL31006
    Dirksland, Netherlands
  • Site NL31001
    Haarlem, Netherlands
  • Site NL31002
    Rotterdam, Netherlands
  • Site NL31004
    Rotterdam, Netherlands
  • Site NL31012
    Rotterdam, Netherlands
  • Site NL31009
    Terneuzen, Netherlands
  • Site PO48019
    Poznan, Skorzewo, Poland
  • Site PO48005
    Bialystok, Poland
  • Site PO48006
    Bydgoszcz, Poland
  • Site PO48004
    Katowice, Poland
  • Site PO48017
    Katowice, Poland
  • Site PO48015
    Krakow, Poland
  • Site PO48021
    Krakow, Poland
  • Site PO48007
    Lodz, Poland
  • Site PO48012
    Lodz, Poland
  • Site PO48002
    Poznan, Poland
  • Site PO48018
    Poznan, Poland
  • Site PO48010
    Szczecin, Poland
  • Site PO48003
    Świdnik, Poland
  • Site PO48001
    Warsaw, Poland
  • Site ES34011
    Barcelona, Spain
  • Site ES34020
    Barcelona, Spain
  • Site ES34010
    Elche, Spain
  • Site ES34003
    Girona, Spain
  • Site ES34005
    Granada, Spain
  • Site ES34006
    Jaén, Spain
  • Site ES34017
    León, Spain
  • Site ES34007
    Madrid, Spain
  • Site ES34019
    Madrid, Spain
  • Site ES34022
    Madrid, Spain
  • Site ES34023
    Madrid, Spain
  • Site ES34015
    Majadahonda, Spain
  • Site ES34002
    Murcia, Spain
  • Site ES34014
    Murcia, Spain
  • Site ES34008
    Palma, Spain
  • Site ES34025
    Rivas-Vaciamadrid, Spain
  • Site ES34009
    Seville, Spain
  • Site ES34024
    Seville, Spain
  • Site ES34013
    Valencia, Spain
  • Site GB44008
    Bebington, Birkenhead, United Kingdom
  • Site GB44009
    Guildford, Surrey, United Kingdom
  • Site GB44018
    Aberdeen, United Kingdom
  • Site GB44019
    Birmingham, United Kingdom

Showing the first 100 of 110 sites across 11 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Liao C, Pal L. Novel Pharmacotherapies for Menopausal Symptoms. Obstet Gynecol. 2025 Oct 1;146(4):473-486. doi: 10.1097/AOG.0000000000006025. Epub 2025 Aug 7. PubMed 40773756 ↗

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jun 2026, 22 months.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Jul 31, 2024
Primary completionActual
Jun 25, 2026
CompletionEst.
Apr 30, 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06440967
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Jul 31, 2024
Primary completion
Jun 25, 2026
Completion
Apr 30, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion